BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRXBioLineRx(BLRX) prnewswire.com·2024-05-28 19:00
  • Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University - - ...